Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

May 2, 2017

Checkpoint Molecule Measurements Not Reliable for Mesothelioma Research, Editorial Argues

News

Examining the presence of PD-L1 molecules in a tumor as a test to predict if therapy with immune checkpoint inhibitors will work is a highly controversial area in this field ... Read more

April 25, 2017

Phase 1 Trial Suggests Tiziana’s Milciclib Benefits Mesothelioma Patients

News

A combination of Tiziana Life Sciences‘ milciclib and the intravenous chemotherapy Gemzar (gemcitabine) stabilized tumor growth in a small group of patients with advanced solid tumors, including mesothelioma, according to a ... Read more

April 19, 2017

Researchers Suggest Surface Molecules May Pair to Act as Diagnostic Biomarkers in Mesothelioma

News

Researchers suggest that a cell surface molecule called CD44, and its interaction with a protein called hyaluronan, might be used as diagnostic biomarkers in malignant pleural mesothelioma, with the possibility ... Read more

March 30, 2017

Mesothelioma Patients Who Receive IMPRINT Radiotherapy Live Longer, Study Shows

News

Mesothelioma patients treated with chemotherapy and a modern type of radiotherapy called IMPRINT survive longer after lung-sparing surgery than patients who received conventional radiotherapy, an analysis of patient outcomes indicates. ... Read more

March 21, 2017March 21, 2017

Benefits of Keytruda in Early Pleural Mesothelioma Trial Justifies Further Studies

News

Keytruda (pembrolizumab) may benefit patients with with malignant pleural mesothelioma by targeting tumors that produce the immune checkpoint molecule PD-L1, according to an interim analysis of a Phase 1b study. The treatment ... Read more

February 28, 2017

New Generation of CAR T-cells May Be Effective Against Mesothelioma

News

A new generation of CAR T-cell immunotherapy shows promising results in preclinical models of malignant mesothelioma, prompting researchers to suggest the treatment should be evaluated in clinical trials. In contrast to ... Read more

February 22, 2017

Outcome-prediction Tool Developed for Mesothelioma Patients with Relapses

News

Researchers have developed a three-factor tool to predict which malignant mesothelioma patients with relapses are likely to have better outcomes and which poorer outcomes. One benefit of the prognosis tool ... Read more

February 17, 2017February 17, 2017

Progression-Free Survival Not Valid Substitute for Overall Survival as Mesothelioma Measure, Study Says

News

Measures of progression-free survival cannot be used as substitute measures for overall survival in clinical trials of malignant mesothelioma, according to an analysis of data from 17 trials. The findings ... Read more

February 14, 2017

Virus in Mesothelioma Cells Could Become New Way to Treat the Cancer, Study Reports

News

A virus that infects only mesothelioma cells producing a specific growth factor could be used to treat malignant pleural mesothelioma, according to a Japanese study that reported the therapy generated ... Read more

February 13, 2017February 13, 2017

Study Links Poverty to Shorter Survival for Mesothelioma Patients

News

Poor people with mesothelioma live shorter lives and are less likely to get chemotherapy than those with higher incomes, though geographical distance to oncological specialty care has no effect on survival, a ... Read more